The Safety, Tolerability and Preliminary Efficacy of AV411, a Glial Activation Inhibitor, in Heroin Abusers Under Conditions of Morphine Maintenance and Withdrawal

Trial Profile

The Safety, Tolerability and Preliminary Efficacy of AV411, a Glial Activation Inhibitor, in Heroin Abusers Under Conditions of Morphine Maintenance and Withdrawal

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Ibudilast (Primary)
  • Indications Opioid abuse
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 16 Jun 2015 According to a MediciNova media release, results published in the journal Addiction Biology.
    • 07 Sep 2014 Columbia University and the New York State Psychiatric Institute have received a grant from the National Institute on Drug Abuse (NIDA) to enable completion of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top